Shares of Medanta operator Global Health close 24% higher on debut trade: Experts recommend if investors should buy, sell or hold
Medanta operator Global Healths shares made a decent debut on the exchanges today as it listed over 19 per cent premium to Rs 401 apiece on the NSE and BSE against the issue price of Rs 336 at the upper end.
Shares of Global Health Limited, which operates a hospital chain under the Medanta brand, closed around 24 per cent to Rs 417.3 per share on the NSE as compared to the issue price of Rs 336 apiece on the first day of its trading session on Wednesday.
Medanta operator Global Health's shares made a decent debut on the exchanges today as it listed over 19 per cent premium to Rs 401 apiece on the NSE and BSE against the issue price. The Rs 2206-crore initial public offer (IPO), which was launched between November 3-7, 2022, had received nearly 10 times subscriptions.
The stock had made a 52-week high of 424.65 per share, while the 52-week low of 390.55 per share on the NSE at the time of listing, during the early morning session today.
Also Read: Medanta building 1,000-bed hospital in Noida
In his recommendation, Zee Business Managing Editor Anil Singhi said, “Short-term investors place a stoploss at the issue price or Rs 345 and HOLD, while long-term investors can also keep this stock in their portfolio.”
Earlier, Zee Business Managing Editor Anil Singhvi had recommended investors subscribe to Medanta IPO for long-term gains.
"There are chances of some listing gains but considering the sentiments of Indian share markets and uncertainties in the global market; ‘one should focus on long-term gains.’ I usually suggest short-term listing gains only when I see a clear upside of 20-25 per cent," Singhvi had said.
Also Read: Medanta operator Global Health raises Rs 662 crore from anchor investors ahead of IPO
“With long-term structural factors supporting growth, renewed impetus from PMJAY (Pradhan Mantri Jan Arogya Yojana), and the government's focus shifting onto the healthcare sector and delivery market is expected to grow at 13–15 per cent,” Parth Nyati, Founder at Tradingo said.
He added, “The issuer has good patient volumes and cost efficiency, and its financial profile also shows an increasing trend. Finally, the issue is fairly priced at a P/E of 43 as compared to the average industry P/E of 51.93. Those who applied for listing gains can maintain a stop loss of Rs. 380.”
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.